Home > Insider Trading > Filing (0001453687-24-000128)

Filing Details

Accession Number:: 0001453687-24-000128
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-11-18 19:23:47
Reporting Period:: 2024-11-14

Accepted Time:: 2024-11-18 19:23:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1453687	Cartesian Therapeutics Inc.	RNAC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2000226	M Christopher Jewell	C/O Cartesian Therapeutics, Inc. 7495 New Horizon Way Frederick MD 21703	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-11-14	36,050	$3.23	61,990	No	4	M	Direct
Common Stock	Disposition	2024-11-14	18,550	$16.34	43,440	No	4	S	Direct
Common Stock	Disposition	2024-11-14	17,500	$17.02	25,940	No	4	S	Direct
Common Stock	Acquisiton	2024-11-15	16,065	$3.23	42,005	No	4	M	Direct
Common Stock	Disposition	2024-11-15	16,065	$17.06	25,940	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-11-14	36,050	$0.00	36,050	$3.23
Common Stock	Stock Option (Right to Buy)	Disposition	2024-11-15	16,065	$0.00	16,065	$3.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
106,497		2033-01-15	No	4	M	Direct
90,432		2033-01-15	No	4	M	Direct

Footnotes

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.
On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.